Partnerships and collaborations fuel antibodies market growth

Detecting antibodies in a lab

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, predicts.  

In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three cancer targets. 

The collaboration will make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Sanofi is now working on an ADC, which is an antibody designed to carry powerful anti-cancer medications to tumour cells expressing a certain protein. 

More recently, Mersana Therapeutics and a subsidiary of Merck entered a research collaboration to discover ADCs directed against up to two targets.

Drug discovery product launches 

Increasing product launches by market players are expected to drive growth of the global research antibodies market. For instance, in April 2019, ImmunoPrecise launched DeepDisplay Antibody Discovery Platform with an unknown US-based pharma company. 

In contrast to conventional technologies, DeepDisplay uses a transgenic animal immunisation combined with phage display antibody selection to deliver the most therapeutically-relevant antibodies in the shortest amount of time with the highest chances of success.

Antibody therapy approvals

New product approvals will also drive growth. In April 2021, Gilead Sciences announced that Trodelvy (sacituzumab govitecan-hziy), for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, had received full approval from the US Food and Drug Administration (FDA). Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate that combines a humanised monoclonal antibody. 

Key companies operating in the antibodies market include Thermo Fisher Scientific, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology, F Hoffmann La Roche, Novartis, Takeda Pharmaceutical Company, Agilent Technologies, Danaher, BioLegend, Illumina, Phoenix Pharmaceuticals and Abcam. 

The report ‘Research Antibodies Market, by Product Type, by Form, by Source, by Application, by End User, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2022-2030′ is now available from  



Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free